- Home
- MFH vs OCGN Comparison
MFH vs OCGN Comparison
Compare MFH & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFH
- OCGN
- Stock Information
- Founded
- MFH 2011
- OCGN 2013
- Country
- MFH United States
- OCGN United States
- Employees
- MFH N/A
- OCGN N/A
- Industry
- MFH Finance: Consumer Services
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MFH Finance
- OCGN Health Care
- Exchange
- MFH Nasdaq
- OCGN Nasdaq
- Market Cap
- MFH 386.1M
- OCGN 321.7M
- IPO Year
- MFH N/A
- OCGN N/A
- Fundamental
- Price
- MFH $7.86
- OCGN $1.07
- Analyst Decision
- MFH
- OCGN Strong Buy
- Analyst Count
- MFH 0
- OCGN 3
- Target Price
- MFH N/A
- OCGN $6.00
- AVG Volume (30 Days)
- MFH 182.3K
- OCGN 1.7M
- Earning Date
- MFH 04-30-2025
- OCGN 11-07-2025
- Dividend Yield
- MFH N/A
- OCGN N/A
- EPS Growth
- MFH N/A
- OCGN N/A
- EPS
- MFH N/A
- OCGN N/A
- Revenue
- MFH N/A
- OCGN $4,754,000.00
- Revenue This Year
- MFH N/A
- OCGN N/A
- Revenue Next Year
- MFH N/A
- OCGN N/A
- P/E Ratio
- MFH N/A
- OCGN N/A
- Revenue Growth
- MFH 125.92
- OCGN N/A
- 52 Week Low
- MFH $1.03
- OCGN $0.52
- 52 Week High
- MFH $8.86
- OCGN $1.29
- Technical
- Relative Strength Index (RSI)
- MFH 66.06
- OCGN 59.13
- Support Level
- MFH $5.24
- OCGN $1.00
- Resistance Level
- MFH $8.32
- OCGN $1.05
- Average True Range (ATR)
- MFH 0.86
- OCGN 0.03
- MACD
- MFH 0.17
- OCGN 0.00
- Stochastic Oscillator
- MFH 87.15
- OCGN 100.00
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").